

**Ammoren E. Dohm, MD**

**Ironwood Cancer and Research Centers**

**Division of Radiation Oncology**

Radiation Oncologist

**Education:**

2020-2024

**Resident, Department of Radiation Oncology**

Moffitt Cancer Center, Tampa, FL

2019-2020

**Resident, Department of Transitional Medicine**

Spartanburg Regional Healthcare System  
Spartanburg, SC

2015-2019

**Doctor of Medicine**

Wake Forest School of Medicine  
Winston-Salem, NC

**Professional Experience:**

8/2024-Present

Physician, Division of Radiation Oncology,  
Ironwood Cancer & Research Centers, Scottsdale

**Activities and Honors:**

**Certifications:**

American Radium Society

American College of Radiotherapy and Oncology

Radiological Society of North America

Association of Residents in Radiation Oncology

American Medical Association

*Awards, Honors and Committees:*

Chief Resident, Department of Radiation Oncology, Moffitt Cancer Center

Clinical Science Abstract Award Winner, Moffitt Scientific Symposium

Clinical Science Featured Poster, Moffitt Scientific Symposium

Resident Basic Science Research Award, American Society for Radiation Oncology

Bowmen and James Gray Scholar, Wake Forest School of Medicine

Medical Scholars Full-tuition Scholarship, Wake Forest School of Medicine

DEAC Distinguished Volunteer Award, Wake Forest Baptist Medical Center Free Clinic

**Professional Memberships:**

American Society for Radiation Oncology

**Publications:**

**Research Articles**

- 1 **Dohm AE**, Nakashima JY, Kalagotla, H.Ahmed, KA. *Stereotactic Radiosurgery and Anti-PD-1+CTLA-4 Therapy, Anti-PD-1 Therapy, Anti-CTLA-4 Therapy, BRAF/MEK Inhibitors, BRAF Inhibitors, or Conventional Chemotherapy for the Management of Melanoma Brain Metastases.* Eur J Cancer. 2023 Aug 7. DOI: <https://doi.org/10.1016/j.ejca.2023.113287>
- 2 **Dohm AE**, Tang JD, Mills MN, Perez B, Robinson TJ, Creelan B,..Ahmed KA. *Clinical outcomes of non–small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone.* J Neurosurg. 2022 Nov 11. PMID: [36681988](https://pubmed.ncbi.nlm.nih.gov/36681988/).

- 3 **Dohm AE**, Oliver DE, Michael Yu HH, Ahmed KA. Commentary: From Postoperative to Preoperative: *A Case Series of Hypofractionated and Single-Fraction Neoadjuvant Stereotactic Radiosurgery for Brain Metastases*. Oper Neurosurg (Hagerstown). 2022 Apr 11. PMID: [35404318](#).
- 4 Sandoval ML, **Dohm AE**, Yamoah K. *Management of early-stage metastatic prostate cancer: appraisal of locoregional treatments and radiation therapy, with or without immunomodulation*. Endocr Relat Cancer. 2021 Jul 15;28(8):T109-T120. PMID: [34061766](#).
- 5 **Dohm AE**, Nickles TM, Miller CE, Bowers HJ, Miga MI, Attia A, Chan MD, Weis JA. *Clinical assessment of a biophysical model for distinguishing tumor progression from radiation necrosis*. Med Phys. 2021 Jul;48(7):3852-3859. PMID: [34042188](#).
- 6 **Dohm AE**, Diaz R, Nanda RH. *The Role of Radiation Therapy in the Older Patient*. Curr Oncol Rep. 2021 Jan 2;23(1):11. PMID: [33387104](#).
- 7 Helis CA, Hughes RT, Glenn CW, Lanier CM, Masters AH, **Dohm AE**, Ahmed T, Ruiz J, Triozzi P, Gondal H, Cramer CK, Tatter SB, Laxton AW, Xing F, Lo HW, Su J, Watabe K, Wang G, Whitlow CT, Chan MD. *Predictors of Adverse Radiation Effect in Brain Metastasis Patients Treated with Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy*. Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):295-303. PMID: [32615262](#).
- 8 **Dohm AE**, Su J, McTyre ER, Taylor JM, Miller LD, Petty WJ, Xing F, Lo HW, Metheny-Barlow LJ, O'Neill S, Bellinger C, Dotson T, Pasche B, Watabe K, Chan MD, Ruiz J. *Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial*. Int J Biol Markers. 2019 Mar;34(1):90-97. PMID: [30854931](#).
- 9 **Dohm AE**, Hughes R, Wheless W, Lecompte M, Lanier C, Ruiz J, Watabe K, Xing F, Su J, Cramer C, Laxton A, Tatter S, Chan MD. *Surgical resection and postoperative radiosurgery versus staged radiosurgery for large brain metastases*. J Neurooncol. 2018 Dec;140(3):749-756. PMID: [30367382](#).
- 10 Randolph DM, McTyre E, Klepin H, Peiffer AM, Ayala-Peacock D, Lester S, Laxton AW, **Dohm AE**, Tatter SB, Shaw EG, Chan MD. *Impact of radiosurgical management of geriatric patients with brain metastases: Clinical and quality of life outcomes*. J Radiosurg SBRT. 2017;5(1):35-42. PMID: [29296461](#).
- 11 **Dohm AE**, McTyre ER, Okoukoni C, Henson A, Cramer CK, LeCompte MC, Ruiz J, Munley MT, Qasem S, Lo HW, Xing F, Watabe K, Laxton AW, Tatter SB, Chan MD. *Staged Stereotactic Radiosurgery for Large Brain Metastases: Local Control and Clinical Outcomes of a One-Two Punch Technique*. Neurosurgery. 2018 Jul 1;83(1):114-121. PMID: [28973432](#).

12 **Dohm AE**, McTyre ER, Chan MD, Fan C, Isom S, Bourland JD, Mott RT, Cramer CK, Tatter SB, Laxton AW. *Early or late radiotherapy following gross or subtotal resection for atypical meningiomas: Clinical outcomes and local control.* J Clin Neurosci. 2017 Dec;46:90-98. PMID: [28917587](#).

## Presentations

- 1 Tang J, **Dohm AE**, Kalagotla H, Bhandari M, Oliver D. Clinical Outcomes in the Management of Melanoma Brain Metastases Treated with Stereotactic Radiosurgery and Anti-PD-1+CTLA-4. Poster Presentation at 2022 SNO Annual Meeting, Tampa, FL. 2022 Nov 7.
- 2 **Dohm AE**, Kalagotla H, Jiang SX, Bhandari M, Mills MN, Kim Y, Ahmed KA. Stereotactic Radiosurgery and Anti-PD-1 Therapy, Anti-PD-1 + CTLA-4 Therapy, Anti-CTLA-4 Therapy, BRAF/MEK Inhibitors, BRAF Inhibitor, or Conventional Chemotherapy for the Management of Melanoma Brain Metastases. Poster presentation at 2022 ASTRO Annual Meeting, Chicago, IL. 2022 Oct 24.
- 3 **Dohm AE**, Tang JD, Mills MN, Perez B, Robinson TJ, Creelan B, Ahmed KA. Upfront Treatment with Osimertinib versus Osimertinib and Radiotherapy in Patients with EGFR-Positive Non-small Cell Lung Cancer Brain Metastases. Poster presentation at 2021 Multidisciplinary Thoracic Cancers Symposium, Scottsdale, AZ. 2021 December 3.
- 4 **Dohm AE**, Tang JD, Mills MN, Perez B, Robinson TJ, Creelan B, Ahmed KA. Clinical Outcomes of Non-Small Cell Lung Cancer Brain Metastases Treated with Stereotactic Radiosurgery and Immune Checkpoint Inhibitors, EGFR Tyrosine Kinase Inhibitors, Chemotherapy, and Immune Checkpoint Inhibitors, or Chemotherapy Alone. Poster presentation at 2021 ASTRO, Chicago, IL. 2021 Oct 20.
- 5 **Dohm AE**, Sim AJ, Mohammadi H, Frakes JM, Rosenberg SA, Harmon GG, Hoffe SE. Cultivating Care Team Success within the Radiation Oncology Department by Leveraging the DiSC Assessment. Oral presentation at 2021 ROECSG Sping Symposium, Virtual. 2021 May 14.
- 6 **Dohm AE**, Kalagotla H, Jiang SX, Bhandari M, Mills MN, Kim Y, Ahmed KA. Stereotactic Radiosurgery and Anti-PD-1 Therapy, Anti-PD-1 + CTLA-4 Therapy, Anti-CTLA-4 Therapy, BRAF/MEK Inhibitors, BRAF Inhibitor, or Conventional Chemotherapy for the Management of Melanoma Brain Metastases. Oral presentation at 2021 Moffitt Scientific Symposium, Tampa, FL. 2021 May 11.
- 7 **Dohm AE**, Nickles T, Johnson H, Miga M, Attia A, Chan MD, Weis JA. Imaging-driven Biophysical Model for the Differentiation of Tumor Progression from Radiation Necrosis. Oral presentation at 2021 ASTRO Annual Meeting, Chicago, IL. 2021 Sept 16.

8 Bjornn D, **Dohm AE**, South M, Crowley MJ, Larson MJ. ERP signatures of Rule Violation and Association with Repetitive Behavior in ASD. Oral presentation at 2019 International Society for Autism Research. Atlanta, GA. 2019 May 16.

9 **Dohm AE**, Hughes RE, Wheless W, Lecompte M, Lanier C, .Chan MD. Comparison of Treatment Modalities for Large Brain Metastases. Poster presentation at 2018 American Society for Radiation Oncology, San Antonio, TX. 2018 Oct 22.

10 Nickles T, **Dohm AE**, Chan MD, Weis JA. Imaging-Based Biophysical Modeling to Differentiate Radiation Necrosis from Tumor Recurrence Following Stereotactic Radiosurgery for Brain Metastasis. Poster presentation at 2018 Biomedical Engineering Society, Atlanta, GA. 2018 Oct 20.

11 **Dohm AE**, Su J, McTyre E, Soike MH, Miller LD, Petty WJ, .Ruiz J. Determination of Tumor Gene Expression in Non-small Cell Lung Cancer Patients Who Develop Brain Metastasis Diagnosis: Analysis of a Prospective Trial. Poster presentation at 2017 American Society for Radiation Oncology, San Diego, CA. 2017 Sept 26.

12 **Dohm AE**, Mckay W, West J, Wolfe S. Non-emergent carotid artery stenting following mechanical thrombectomy for acute ischemic stroke. Poster presentation at 2016 WFUSOM Research Fair, Winston-Salem, NC. 2016 Oct 16.

13 **Dohm AE**, McTyre E, Okoukoni C, Henson A, Cramer CK, LeCompte M, Ruiz J, ...Chan MD. Staged Stereotactic Radiosurgery for Large Brain Metastases: Local Control and Clinical Outcomes of a One-Two Punch Technique. Poster presentation at Medical School Research Day, Winston-Salem, NC. 2016 Oct 6.

14 **Dohm AE**. The Ethics of Stem Cell Research Applications in Parkinson's Disease. Poster presentation at Neuroscience Research Day, Provo, UT. 2014, April 18.

15 **Dohm AE**, Sanchez J, Stotsky-Himelfarb E, Willingham FF, Hoffe S. Strategies to Minimize Late Effects from Pelvic Radiotherapy. Am Soc Clin Oncol Educ Book. 2021 Mar;41:158-168. PMID: 34010045.

## **Research Trials:**

Sub investigator in Ironwood Cancer and Research Centers trials, please refer to website for details.